Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328374 | 0.86 | FFAR3 (0.32) | ALDH1A1FFAR3 | |
| SCHEMBL24328382 | 0.86 | FFAR3 (0.32) | ALDH1A1FFAR3 | |
| SCHEMBL1254874 | 0.86 | FFAR3 (0.32) | ALDH1A1FFAR3 | |
| SCHEMBL1468175 | 0.85 | — | — | |
| SCHEMBL29108746 | 0.82 | FFAR3 (0.32) | FFAR3CYP2C19NPSR1SMN1; SMN2LMNA | |
| SCHEMBL12735418 | 0.81 | SMN1; SMN2 (0.33) | ALDH1A1CYP2C19CYP3A4CYP2C9PKM | |
| SCHEMBL2300431 | 0.80 | FFAR3 (0.38) | FFAR3CYP2C19TSHRNPSR1CYP4F2 | |
| SCHEMBL5634851 | 0.80 | — | — | |
| SCHEMBL24780855 | 0.79 | CYP3A4 (0.36) | ALDH1A1CYP2C19CYP3A4CYP2C9PKM | |
| SCHEMBL25841430 | 0.79 | CYP3A4 (0.42) | ALDH1A1CYP2C19CYP3A4CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737453-A1 | NOVEL SELENOPHENE DERIVATIVES | Aigen Sciences Inc. (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-12516067-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2025-05-08 | — | — | US | disclosed |
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| WO-2025005748-A1 | NOVEL SELENOPHENE DERIVATIVES | (주)아이젠사이언스 | 2025-01-02 | — | — | WO | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4430055-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-118541365-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2024-08-23 | — | — | CN | disclosed |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021119265-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008093064-A1 | L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | ALDH1A1 2997/4885FFAR3 148/4885CYP2C19 429/4885 |
| US-20240228468-A1 | N-(6-((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YI)AMINO)PYRIDAZIN-3-YL)PHENYL)CARBOXAMIDE AND (6- ((OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)BENZAMIDE DERIVATIVES AS MACHR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | CHRM5, CHRM1, CHRM2 | ALDH1A1 1704/4885FFAR3 549/4885CYP2C19 1770/4885 |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | ALDH1A1 345/4885FFAR3 2164/4885CYP2C19 4749/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | ALDH1A1 1572/4885FFAR3 438/4885CYP2C19 151/4885 |
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | DCTD, NUDT1, TYMP | ALDH1A1 3272/4885FFAR3 3856/4885CYP2C19 647/4885 |
| US-20250145595-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | ALDH1A1 1885/4885FFAR3 247/4885CYP2C19 1671/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | ALDH1A1 2997/4885FFAR3 148/4885CYP2C19 429/4885 |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | ALDH1A1 3979/4885FFAR3 246/4885CYP2C19 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.